Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study

Volume: 21
Published: Dec 13, 2021
Abstract
No abstract.
Paper Details
Title
Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
Published Date
Dec 13, 2021
Volume
21
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.